Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression changes following dihydrotestosterone (DHT) treatment in HCI-009 PDXs

ABSTRACT: Gene expression changes following dihydrotestosterone (DHT) treatment in HCI-009 PDXs

PROVIDER: PRJNA638700 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11992827.fastq.gz	Fastqsanger.gz
	SRR11992828.fastq.gz	Fastqsanger.gz
	SRR11992829.fastq.gz	Fastqsanger.gz
	SRR11992830.fastq.gz	Fastqsanger.gz
	SRR11992831.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 7

Similar Datasets

Gene expression changes following dihydrotestosterone (DHT) treatment in HCI-009 PDXs

Project description:Triple-negative breast cancer (TNBC) is aggressive and difficult, and few targeted therapies are available to treat this patient population. The androgen receptor (AR) has emerged as a potential target in breast cancer. Newer generation AR inhibitors, such as Seviteronel (Sevi), are unique in their ability to inhibit AR both directly and by blocking upstream androgen synthesis. The purpose of this study was to investigate the pre-clinical activity of Sevi in TNBC and further explore the effectiveness of targeting both androgen biosynthesis and AR activity in combination with other downstream acting agents. AR overexpressing (AR+) TNBC cell lines, xenografts and androgen responsive patient-derived xenograft (PDX) models were using to show how effectively Sevi inhibits AR activity and cell/tumor proliferation. Single cell RNA-sequencing of the AR+ cell line MDA-MB-453 illustrated heterogeneity in AR levels and identified cell cycle pathway activation in ARHigh versus ARLow expressing cells. Combination treatment with the cell cycle CDK4/6 inhibitor abemaciclib and Sevi showed synergy in AR+ TNBC cells and increased effectiveness, compared to each drug alone, in an AR+ TNBC xenograft model. While cell cycle inhibitors have been approved for use in hormone-receptor positive breast cancer, our studies suggest that these drugs may be equally effective in AR+ TNBC cells, especially when combined with AR antagonists. Implications. These data suggest that targeting AR signaling at multiple points throughout the pathway may be an effective was to treat patients with AR+ TNBC.

2020-06-11 | GSE152246 | GEO

Gene expression changes following seviteronel (Sevi) treatment in HCI-009 PDXs

Project description:Gene expression changes following seviteronel (Sevi) treatment in HCI-009 PDXs

| PRJNA638952 | ENA

Androgen receptor cistrome in breast cancer cell line MDA-MB-453 with 5a-dihydrotestosterone (DHT) stimulation

Project description:Androgen receptor (AR) is expressed in 60-70% of breast cancers independent of estrogen receptor (ER) expression, however its function in breast cancer is largely unknown. Our study identified the high level of AR in ERâ??/HER2+ breast tumors and andorgen and AR greatly stimulated growth of MDA-MB-453 breast cancer cells. To define the genome-wide AR binding sites, we performed AR ChIP-seq using MDA-MB-453 breast cancer cells followig stimulation of DHT. We also identified FOXA1 is a crucial AR cofactor in MDA-MB-453 cells and the FOXA cistrome showed signaficant overlap with AR at both early and late time points of DHT stimulation. AR ChIP was performed in MDA-MB-453 breast cancer cells following 5a-dihydrotestosterone (DHT) stimulation for 4h and 16h respectively. FOXA1 ChIP-seq was performed after 4h DHT stimulation in MDA-MB-453 cells.

2011-07-11 | E-GEOD-28788 | biostudies-arrayexpress

Effect of 5a-dihydrotestosterone on breast cancer cell line MDA-MB-453

2011-07-11 | GSE28305 | GEO

Adipose tissue of gonadectomized mice injected with dihydrotestosterone

Project description:Comparison of retroperitoneal adipose tissue of intact male mice and gonadectomized C57BL6 male mice. Gonadectomized mice were untreated or injected with dihydrotestosterone (DHT) and sacrificed 3 or 24 hours after injection. Keywords: other

2004-04-24 | GSE1091 | GEO

Gene expression changes following seviteronel (Sevi) treatment in HCI-009 PDXs

2020-06-12 | GSE152318 | GEO

Effect of 5a-dihydrotestosterone on breast cancer cell line MDA-MB-453

Project description:Analysis of MDA-MB-453 breast cancer cells treated with the androgen 5a-dihydrotestosterone (DHT) for 6h, 16h and 48h to define the genes that are differentially regulated in response to DHT. MDA-MB-453 breast cancer cells were treated with 5a-dihydrotestosterone (DHT) for time course, followed by RNA extraction and hybridization on Affymetrix microarrays, in order to obtain the gene expression profiles at three time points. The vehicle treated samples are used as control.

2011-07-11 | E-GEOD-28305 | biostudies-arrayexpress

Expression data from ovaries and adipose tissue in hyperandrogenized(DHT-treated) mice

Project description:Mice under chronic dihydrotestosterone (DHT) exposion represented reproductive and metabolic disorders, which were based on the dysfunction of ovaries and fat tissues. We used microarrays to detail the global programme of gene expression and identified distinct difference in ovaries and gonadal fat pads between DHT-treated mice and control.

2021-04-04 | GSE171431 | GEO

Dihydrotestosterone induced changes in gene expression in immortalized human conjunctival epithelial cells

Project description:Genome-wide analysis of dihydrotestosterone (DHT) induced changes in gene expression in immortalized human conjunctival epithelial cells. Analysis of regulation of immortalized human conjunctival epithelial cells by dihydrotestosterone at gene expression level. The hypothesis tested in the present study was that the androgen-eye interaction in ocular surface epithelial cells like conjunctival cells is influenced by androgens through regulation of the expression of multiple genes. Results provide important information of the differential regulation of numerous genes in response to dihydrotestosterone incubation of immortalized human conjunctival epithelial cells.

2011-03-31 | GSE18094 | GEO

Expression data from DHT stimulation vs. control in LNCaP cells

Project description:Expression data from DHT stimulation vs. control in LNCaP cells LNCaP cells were maintained in phenol red-free RPMI supplemented with 10% charcoal/dextran stripped FCS for three days before stimulation with 100 nM dihydrotestosterone (DHT) for 48 hours

2010-02-21 | E-GEOD-14988 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data